Just looking in a bit more detail on the parvulus website. Interesting that the CEO of Parvulus is Jason Loveridge- also director of ASX co Resonance Health.
Am I correct in thinking the info below means the product has been granted "orphan status"?
"Parvulus Suisse SA has received a Humanitarian Use Device Designation (HUD) from the Office of Orphan Drug Products Development of the Food and Drugs Administration (FDA) for its Intra-annular Annuloplsaty Ring for the surgical treatment of atrioventricular valve regurgitation in the pediatric population.
The Intra-annular Ring received a CE Mark in December 2011 and is now available for use in over 200 countries worldwide."
If so, am I also correct in thinking there is a way shorter timeframe to progress to commercialisation? Are there any other examples of ASX biotech cos developing orphan products?
Just looking in a bit more detail on the parvulus website....
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)